Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Br J Haematol. 2024 Jul;205(1):122-126. doi: 10.1111/bjh.19455. Epub 2024 May 8.
We reviewed cases with aggressive B-cell non-Hodgkin lymphoma who relapsed or progressed following glofitamab. The prognosis was poor, with low rates of response to subsequent salvage therapies, and a median overall survival of 4.1 months from the time of progression. There were high rates of CD20 loss (59%) at the time of relapse. In a field where CD20 × CD3 bispecific antibodies are entering routine clinical use, our experience highlights a potential means of resistance. It illustrates both the need to further characterise mechanisms of CD20 loss, and to pursue clinical trials of novel non-CD20-directed treatments in this cohort.
我们回顾了格罗菲他单抗治疗后复发或进展的侵袭性 B 细胞非霍奇金淋巴瘤病例。预后较差，后续挽救治疗的反应率较低，从进展开始的中位总生存期为 4.1 个月。复发时 CD20 丢失率较高（59%）。在 CD20×CD3 双特异性抗体开始常规临床应用的领域，我们的经验突出了一种潜在的耐药机制。它既说明了进一步阐明 CD20 丢失机制的必要性，也说明了在这一人群中开展新型非 CD20 靶向治疗临床试验的必要性。
